Equities analysts expect Kala Pharmaceuticals (NASDAQ:KALA) to post ($0.45) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Kala Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.49) and the highest estimate coming in at ($0.41). The company is scheduled to report its next earnings report on Monday, June 25th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full-year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.20) to ($1.74). For the next financial year, analysts anticipate that the business will post earnings of ($2.57) per share, with EPS estimates ranging from ($3.38) to ($1.93). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Kala Pharmaceuticals.
Kala Pharmaceuticals (NASDAQ:KALA) last released its earnings results on Monday, March 26th. The company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.09).
Several research firms recently weighed in on KALA. Zacks Investment Research upgraded Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. BidaskClub upgraded Kala Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, April 4th. Wells Fargo reiterated an “outperform” rating and set a $19.00 target price (down from $24.00) on shares of Kala Pharmaceuticals in a research report on Thursday, January 25th. They noted that the move was a valuation call. Finally, Wedbush reiterated an “outperform” rating and set a $46.00 target price on shares of Kala Pharmaceuticals in a research report on Friday, December 22nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $35.80.
In other news, major shareholder Orbimed Advisors Llc purchased 64,637 shares of the company’s stock in a transaction on Wednesday, January 24th. The stock was bought at an average cost of $14.91 per share, for a total transaction of $963,737.67. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have acquired 622,397 shares of company stock valued at $9,273,112 over the last 90 days.
Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in shares of Kala Pharmaceuticals in the third quarter valued at about $540,000. American International Group Inc. acquired a new stake in shares of Kala Pharmaceuticals in the third quarter valued at about $122,000. JPMorgan Chase & Co. acquired a new stake in shares of Kala Pharmaceuticals in the third quarter valued at about $4,037,000. Wells Fargo & Company MN acquired a new stake in shares of Kala Pharmaceuticals in the third quarter valued at about $3,752,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in shares of Kala Pharmaceuticals in the third quarter valued at about $313,000. Institutional investors own 72.30% of the company’s stock.
NASDAQ KALA traded up $0.18 during trading hours on Friday, hitting $16.00. 193,093 shares of the company’s stock were exchanged, compared to its average volume of 327,168. Kala Pharmaceuticals has a 12-month low of $11.81 and a 12-month high of $26.75. The company has a market capitalization of $393.88 and a PE ratio of -2.74. The company has a current ratio of 7.97, a quick ratio of 7.97 and a debt-to-equity ratio of 0.13.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/20/brokerages-expect-kala-pharmaceuticals-kala-to-announce-0-45-eps.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The company's product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease.
Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.